Dutasteride and MK-2866 Interaction
Dutasteride and MK-2866 have a potentially harmful interaction with 64% confidence. Both Dutasteride and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.
Compound Profiles
Dutasteride
Dual 5-Alpha Reductase Inhibitor | Hair Loss & BPH
Dutasteride competitively inhibits both the Type I and Type II isoforms of the enzyme 5-alpha reductase. Type II is the predominant isoform in the prostate and hair follicles, while Type I is found primarily in the skin, sebaceous glands, and liver.
View full profileMK-2866
Selective Androgen Receptor Modulator | Muscle Wasting Research
MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take Dutasteride with MK-2866?
Combining Dutasteride with MK-2866 is not recommended. Both Dutasteride and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Is Dutasteride and MK-2866 safe together?
This combination carries significant risk. Both Dutasteride and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.
What are the interactions between Dutasteride and MK-2866?
Both Dutasteride and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.
How should I time Dutasteride and MK-2866?
Dutasteride has a half-life of ~5 weeks (extremely long; active metabolite accumulation over months) and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.